(2S)-N'-[(1S,2R)-3-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-1-benzyl-2-hydroxy-propyl]-2-(quinoline-2-carbonylamino)butanediamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-N'-[(1S,2R)-3-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-1-benzyl-2-hydroxy-propyl]-2-(quinoline-2-carbonylamino)butanediamide
• 英文别名: (2S)-N'-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide
• 化学式: C₃₈H₅₀N₆O₅
• 分子量: 670.8
• InChiKey: PGRJGTIQQBRXJV-UGJKXSETSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  49
• 可旋转键数：
  13
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  167
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• PROCESS FOR SYNTHESIS OF SYN AZIDO EPOXIDE AND ITS USE AS INTERMEDIATE FOR THE SYNTHESIS OF AMPRENAVIR & SAQUINAVIR
  申请人：Council of Scientific & Industrial Research

  公开号：US20150011782A1

  公开（公告）日：2015-01-08

  Disclosed herein is a novel route of synthesis of syn azide epoxide of formula 5, which is used as a common intermediate for asymmetric synthesis of HIV protease inhibitors such as Amprenavir, Fosamprenavir, Saquinavir and formal synthesis of Darunavir and Palinavir obtained by Cobalt-catalyzed hydrolytic kinetic resolution of racemic anti-(2SR,3SR)-3-azido-4-phenyl-1,2-epoxybutane (azido-epoxide).

  本文披露了一种合成公式5的syn叠氮环氧化物的新路线，该化合物被用作HIV蛋白酶抑制剂的不对称合成的常见中间体，如Amprenavir、Fosamprenavir、Saquinavir以及通过钴催化的拆分手性反式-(2SR,3SR)-3-叠氮-4-苯基-1,2-环氧丁烷(叠氮环氧化物)合成Darunavir和Palinavir。
• NOVEL POLYMORPHS OF SAQUINAVIR
  申请人：Parthasaradhi Reddy Bandi

  公开号：US20120035211A1

  公开（公告）日：2012-02-09

  The present invention provides novel polymorphs of saquinavir, processes for their preparation and pharmaceutical compositions comprising them. The present invention also provides a process for purification of saquinavir. The present invention further provides a novel process for preparation of known saquinavir crystalline form I.

  本发明提供了萨奎那韦的新型多晶型、其制备方法和包含它们的制药组合物。本发明还提供了一种萨奎那韦纯化的过程。本发明进一步提供了一种制备已知的萨奎那韦晶体形式I的新方法。
• Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
  申请人：SIPOS TIBOR

  公开号：US20100021505A1

  公开（公告）日：2010-01-28

  Method of preventing or reducing diarrhea and/or steatorrhea in HIV-positive patients being treated with High Activity Antiretroviral drugs containing protease inhibitors, nucleoside reverse transcriptase inhibitors or non-nucleoside reverse transcriptase inhibitors. The method includes the steps of: administering to the HIV-positive patient a High Activity Antiretroviral drug containing a protease inhibitor, a nucleoside reverse transcriptase inhibitor or a non-nucleoside reverse transcriptase inhibitor; and co-administering with the HAART drug a gastric acid-resistant polymer-coated and buffered digestive enzyme composition containing pancreatic proteases, lipases, co-lipases, nucleases, amylases and other bio-active substances produced by the pancreatic gland.

  预防或减少HIV阳性患者在接受含有蛋白酶抑制剂、核苷酸反转录酶抑制剂或非核苷酸反转录酶抑制剂的高活性抗逆转录病毒药物治疗时出现腹泻和/或脂肪泻的方法。该方法包括以下步骤：给HIV阳性患者口服含有蛋白酶抑制剂、核苷酸反转录酶抑制剂或非核苷酸反转录酶抑制剂的高活性抗逆转录病毒药物；同时与HAART药物联合给予一种胃酸耐受性聚合物包膜和缓冲的消化酶组合物，其中包含胰蛋白酶、脂肪酶、胆脂酶、核酸酶、淀粉酶和胰腺分泌的其他生物活性物质。
• Retroviral protease inhibitors
  申请人：Tally J. John

  公开号：US20080103311A1

  公开（公告）日：2008-05-01

  N-heterocyclic moiety containing hydroxyethylamino compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

  含有羟乙基氨基的N-杂环基团化合物可作为反转录病毒蛋白酶抑制剂，特别是作为HIV蛋白酶的抑制剂。
• US7312333B2
  申请人：——

  公开号：US7312333B2

  公开（公告）日：2007-12-25